Advertisement
Advertisement
PTGX
Protagonist Therapeutics, Inc
136.11
USDSponsored
+0.68
+0.50%
Jul 24, 16:00 UTC -4
Closed
After-Market
136.15
+0.04
+0.03%
PTGX Earnings Reports
Positive Surprise Ratio
PTGX beat 24 of 40 last estimates.
60%
Next Report
Date of Next Report
Aug 04, 2026
Estimate for Q2 26 (Revenue/ EPS)
$216.68M
/$1.98
Implied change from Q1 26 (Revenue/ EPS)
+284.40%
/+3860.00%
Implied change from Q2 25 (Revenue/ EPS)
+3806.95%
/-460.00%
Protagonist Therapeutics, Inc earnings per share and revenue
On May 05, 2026, PTGX reported earnings of 0.05 USD per share (EPS) for Q1 26, beating the estimate of -0.54 USD, resulting in a 109.20% surprise. Revenue reached 56.37 million, compared to an expected 16.60 million, with a 239.59% difference. The market reacted with a -0.31% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 12 analysts forecast an EPS of 1.98 USD, with revenue projected to reach 216.68 million USD, implying an increase of 3860.00% EPS, and increase of 284.40% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
argenx SE - ADR
Report Date
Jul 23, 2026 For Q2 26
Estimate
$6.29
Actual
$7.32
Surprise
+16.38%
NovoCure Limited Ordinary Shares
Report Date
Jul 23, 2026 For Q2 26
Estimate
-$0.33
Actual
-$0.13
Surprise
+61.70%
DBV Technologies S.A.
Report Date
Jul 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.60
Surprise
-494.06%
Lexaria Bioscience Corp. Common Stock
Report Date
Jul 13, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+7.73%
VivoSim Labs, Inc. Common Stock
Report Date
Jul 14, 2026 For Q4 25
Estimate
-$0.19
Actual
-$2.21
Surprise
-1,040.35%
FAQ
What were Protagonist Therapeutics, Inc's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Protagonist Therapeutics, Inc reported EPS of $0.05, beating estimates by 109.2%, and revenue of $56.37M, 239.59% above expectations.
How did the market react to Protagonist Therapeutics, Inc's Q1 2026 earnings?
The stock price moved down -0.31%, changed from $99.52 before the earnings release to $99.21 the day after.
When is Protagonist Therapeutics, Inc expected to report next?
The next earning report is scheduled for Aug 04, 2026.
What are the forecasts for Protagonist Therapeutics, Inc's next earnings report?
Based on 12
analysts, Protagonist Therapeutics, Inc is expected to report EPS of $1.98 and revenue of $216.68M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement